GLP-1 Drugs Show Liver Benefits in Fatty Liver Disease Beyond Weight Loss

Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects approximately 30% of the global adult population and is increasingly recognized as a systemic metabolic disorder linked to cardiovascular disease, chronic kidney disease, and malignancy. As global obesity rates climb, MASLD burden is expected to escalate substantially. This 2025 review, authored by researchers from Peru and Mexico and published in the World Journal of Gastroenterology, provides a comprehensive synthesis of the efficacy and safety of anti-obesity medications (AOMs) in MASLD and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH). A literature search spanning PubMed, Scopus, Web of Science, EMBASE, and SciELO through June 2025 identified 155 eligible peer-reviewed studies, of which 35.5% were published within the past five years, reflecting rapid advances in this therapeutic space.

The pathophysiological framework central to the review establishes that insulin resistance drives excess free fatty acid delivery to the liver, triggering lipotoxicity, oxidative stress, reactive oxygen species generation, and activation of hepatic stellate cells — the primary mediators of fibrosis. Inflammatory cytokines including TNF-α, IL-6, and IL-1β perpetuate a self-amplifying injury loop, progressing disease from simple steatosis through steatohepatitis to irreversible cirrhosis. The authors also highlight limitations of non-invasive diagnostic tools: the FIB-4 index can yield false-negative rates exceeding 30% in patients with diabetes or obesity, and vibration-controlled transient elastography (VCTE) with LSM thresholds of 8–12 kPa for fibrotic MASLD and >12 kPa for advanced fibrosis remains the most validated first-line imaging modality.

Among GLP-1 receptor agonists, semaglutide demonstrated histologic improvement in MASH in the NASH-CLD trial (ESSENCE study Phase 3), with significant reductions in liver fat content measured by MRI-PDFF, improvements in ALT and AST levels, and attenuated fibrosis progression. Liraglutide similarly showed hepatic benefit in the LEAN trial, with 39% of treated patients achieving NASH resolution versus 9% on placebo (p=0.019). These effects appear to be mediated both through weight-dependent mechanisms (≥5% body weight loss improves steatosis; ≥10% improves histology significantly) and direct hepatic GLP-1 receptor signaling that reduces de novo lipogenesis and inflammatory activation.

Tirzepatide, a dual GLP-1/GIP agonist approved for obesity, produced up to 22.5% mean body weight reduction in the SURMOUNT-1 trial and is under active investigation in MASLD/MASH (SYNERGY-NASH trial). Preliminary data suggest superior liver fat reduction compared to GLP-1 monotherapy, though histologic outcomes remain pending. Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist in Phase 2, produced the most pronounced weight loss reported for any pharmacological agent to date (~24% at 48 weeks in Phase 2 trials), with meaningful reductions in liver enzymes, though dedicated MASLD histology data are absent. Bupropion-naltrexone and phentermine-topiramate require careful risk-benefit assessment in MASLD patients due to documented hepatotoxic potential and limited liver-specific evidence.

The review underscores a critical knowledge gap: advanced MASLD alters drug pharmacokinetics through impaired hepatic metabolism, reduced protein binding, and altered volume of distribution — yet most clinical trials exclude patients with cirrhosis or significant fibrosis. The authors call for dedicated trials in this high-risk population, standardized histologic endpoints, and individualized treatment algorithms accounting for fibrosis stage, comorbidities, and drug safety profiles. The convergence of obesity pharmacotherapy and hepatology represents a significant clinical opportunity, but evidence-based guidance for the most vulnerable MASLD patients remains insufficient.